(Press-News.org) London, UK, Saturday 12 April 2014: The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014.
The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase inhibitor ABT-333.
"Using this investigational 3D regimen, with or without ribavirin, these studies have demonstrated consistently high cure rates across a number of patient types, including the more difficult-to-treat subtype GT1a, and HCV patients with compensated cirrhosis," said EASL's Scientific Committee Member Dr. Alessio Aghemo, Gastroenterology and Hepatology Unit, Ospedale Maggiore Policlinico, University of Milan. "The impressive SVR12 results seen are consistent with the results from AbbVie's phase II studies," he added.
In the SAPPHIRE-I study, treatment naïve patients with chronic HCV GT1 infection and no evidence of liver cirrhosis, were given 12 weeks of treatment with the 3D regimen plus ribavirin (RBV). After 12 weeks, the overall intention-to-treat SVR12 rate was 96.2%. Even in the more difficult-to-treat subtype GT1a, which made up the majority of patients in this study, the SVR12 rate was 95.3% compared to 98% in GT1b patients.
Dr. Aghemo also presented the results from TURQUOISE-II, which demonstrated the efficacy of the 3D regimen even in HCV GT1a and GT1b patients with cirrhosis. Using an intention-to-treat analysis, in the 12 weeks treatment arm 91.8% of patients achieved SVR12; in the 24 weeks treatment arm, 95.9% of patients achieved SVR12.
Finally, a third study, PEARL-III, studying the efficacy and tolerability of AbbVie's investigational 3D regimen in treatment naïve adults with chronic genotype 1b (GT1b), and no evidence of liver cirrhosis, were randomised to receive the 3D regimen with or without (RBV). Following 12 weeks of treatment, 99.0% receiving the regimen without RBV and 99.5% receiving the regimen with RBV achieved SVR12.
"This collection of studies show encouraging data and further support our understanding of the efficacy and safety of this 3D regimen in a variety of patient types," summarised Dr Aghemo. "Such research continues to highlight the advances being made in treating complex diseases of this type."
Study 1: SAPPHIRE I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAÏVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1
Ninety-six percent SVR12 achieved in treatment naïve HCV Genotype 1 patients on investigational all-oral, interferon-free, 12-week regimen
In the 631-patient SAPPHIRE-I study, treatment-naïve patients chronically infected with HCV GT1, were treated with the 3D regimen plus ribavirin for 12 weeks. Patients were randomized to active treatment for 12 weeks or to start with a placebo for 12 weeks, followed by active treatment. The intention-to-treat SVR12 rate for the 3D regimen for those initially randomized to the active treatment arm was 96.2% (n=455/473). The final SVR12 results for those randomized to start with the placebo treatment are not yet available.
In the active treatment arm, patients with GT1b infection achieved 98 percent SVR12 (148/151), while patients with the more difficult-to-treat subtype GT1a achieved 95.3 percent SVR12 (307/322).
In this intent-to-treat analysis, patients with missing values for any reason were considered treatment failures. The rate of virological relapse or breakthrough was low, occurring in only 0.2% of patients during treatment with the 3D regimen and 1.5% of patients as a post-treatment relapse.
During the double-blind period, the most common treatment-emergent adverse events in the 3D and placebo arms were fatigue (34.7% and 28.5%, respectively) and headache (33.0% and 26.0%, respectively); the frequency of these events did not differ between treatment arms (P=NS). Discontinuation rates due to adverse events were low, and an equal percentage (0.6%) in both active and placebo groups.
"GT1 (with subtypes 1a and 1b) is the most prevalent HCV genotype worldwide," said Dr. Aghemo. "There is currently a large unmet need for a safe, efficacious and simple therapy in this patient population, and this SVR12 rate is superior to the historical SVR12 rate for telaprevir and peginterferon/ribavirin," he added.
The 3D regimen consisted of the NS5B RNA polymerase inhibitor ABT-333 (250mg), ribavirin (weight-based -- 1000mg or 1200mg daily), both dosed twice daily, and the fixed-dose combination of the HCV NS3/4A protease inhibitor ABT-450 (150mg) dosed with ritonavir (100mg) (ABT-450/r 150/100mg) co-formulated with the NS5A inhibitor ABT-267 (25mg).
Study 2: TURQUOISE-II: SVR12 RATES OF 92%-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV)
TURQUOISE-II demonstrates efficacy of 3D regimen even in HCV GT1 patients with cirrhosis
Finally, Dr. Aghemo presented the results from TURQUOISE-II the first completed phase III study investigating an all-oral, interferon-free regimen exclusively in GT1 cirrhotic patients.
From a global study population of 380 GT1a and GT1b, treatment-naive and treatment-experienced patients with compensated cirrhosis: 208 patients were randomised to the 3D regimen with ribavirin (RBV) for 12 weeks, and 172 patients randomised to the 3D regimen with RBV for 24 weeks.
Using an intention-to-treat analysis, in the 12 weeks treatment arm 91.8% of patients (n=191/208) achieved SVR12; in the 24 weeks treatment arm, 95.9% of patients (n=165/172) achieved SVR12. The difference between the two treatment arms was not statistically significant.
Virological relapse or breakthrough was noted in around 6% of patients in the 12-week arm and around 2 percent in the 24-week arm.
The three most common adverse events in the 12-week and 24-week treatment arms were respectively fatigue (32.7% and 46.5%), headache (27.9% and 30.8%) and nausea (17.8% and 20.3%). Discontinuations due to adverse events were noted in approximately 2% of subjects in both treatment arms. The safety profile was consistent with results in non-cirrhotic populations using the 3D with RBV regimen.
Study 3: PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAÏVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN
PEARL-III demonstrates efficacy of 3D regimen with or without ribavirin for treatment of HCV GT1b-infected, non-cirrhotic, treatment-naive adults
This 419-patient studied 3D regimen with or without ribavirin (RBV), in adults with chronic genotype 1b (GT1b) who were new to treatment and had no evidence of liver cirrhosis. Following 12 weeks of treatment, 99.0 percent receiving the 3D regimen with placebo in place of RBV (n=207/209) and 99.5 percent receiving the regimen with RBV (n=209/210) achieved SVR12. High response rates were observed across all HCV GT1b patients in the study, including those patient populations with those characteristics (male gender, Black race and IL28B non-CC genotypes) historically associated with having a decreased response to treatment.
No on-treatment virological failures occurred in the treatment arm without RBV and one single virological failure occurred in the treatment arm with RBV. Across both treatment arms, there were no documented relapses within 12 weeks post-treatment.
INFORMATION:
Disclaimer: the data referenced in this release is based on the submitted abstracts. More recent data may be presented at the International Liver Congress™ 2014.
Notes to Editors
About EASL
EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
EASL's main focus on education and research is delivered through numerous events and initiatives, including:
The International Liver CongressTM which is the main scientific and professional event in hepatology worldwide
Meetings including Monothematic and Special conferences, Post Graduate courses and other endorsed meetings that take place throughout the year
Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field of hepatology
Journal of Hepatology published monthly
Organisation of a Mentorship program and Masterclass to support young investigators starting out on their career path
Participation in a number of policy initiatives at European level
About The International Liver CongressTM 2014
The International Liver Congress™ 2014, the 49th annual meeting of the European Association for the study of the Liver, is being held at ExCel London from April 9 – 13, 2014. The congress annually attracts in excess of 9000 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.
For further information on the studies, or to request an interview, please do not hesitate to contact the EASL Press Office on:
Email: easlpressoffice@cohnwolfe.com
Helena Symeou +44 7976 562 430
Courtney Lock +44 7894 386 422
1. JJ FELD, ET AL. SAPPHIRE I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAÏVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1. ABSTRACT PRESENTED AT THE INTERNATIONAL LIVER CONGRESS™ 2014
2. F POORDAD, ET AL. TURQUOISE-II: SVR12 RATES OF 92%-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267AND ABT-333 PLUS RIBAVIRIN (3D+RBV). ABSTRACT PRESENTED AT THE INTERNATIONAL LIVER CONGRESS™ 2014
3. P FERENCI, ET AL. PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAÏVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN. ABSTRACT PRESENTED AT THE INTERNATIONAL LIVER CONGRESS™ 2014
New interferon-free, all-oral 3D regimen achieves high SVR in chronic HCV genotype 1 patients
2014-04-12
ELSE PRESS RELEASES FROM THIS DATE:
New data for HCV genotype 4 patients with simeprevir- and sofosbuvir-based regimens
2014-04-12
London, UK, Saturday 12 April 2014: Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients.
Overall, 65.4% of patients achieved SVR12 (82.9% of treatment-naïve, 86.4% ...
The Lancet Oncology: Challenges to effective cancer control in China, India, and Russia
2014-04-11
The Lancet Oncology today [Friday 11 April] publishes a major new Commission examining the challenges to effective cancer control in China, India, and Russia – which together experience 46% of all new cancers worldwide, and account for more than half (52%) of all cancer deaths globally. The Commission was led by Professor Paul Goss, of Harvard Medical School and Massachusetts General Hospital Cancer Center, USA, in collaboration with over 40 leading cancer experts from the regions studied, and across the world.
At the same time, the journal also publishes a three part ...
UAlberta researchers examine metabolism in defective cells
2014-04-11
UAlberta researchers are taking a closer look at how two metabolic pathways interact to increase the lifespan of cells with mitochondrial defects. Magnus Friis is the lead author of the study, which was published online on April 10 and will be published in the April 24 issue of Cell Reports.
Mitochondria produce energy for cells through oxidative metabolism, but the process produces toxic byproducts that can accumulate and cause defects in the cell's mitochondria. These defects, in turn, affect the cell's ability to generate energy and can potentially lead to cell death ...
Women with diabetes less likely to have a mammogram: Study
2014-04-11
TORONTO, April 11, 2014 – Women with diabetes are 14 per cent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital.
The study, published today in the journal Diabetic Medicine, is the first to examine the influence of socioeconomic status on the gap in mammogram screening among women with diabetes.
"Managing the demands of a chronic condition such as diabetes is challenging for many women, leaving other preventative actions, ...
BLOODHOUND team predicts the impact of the 1,000 mph supersonic car
2014-04-11
10th of April, 2014 (London). A new paper from the Swansea University, College of Engineering team working on the BLOODHOUND SSC (Supersonic car) project has been published on the aerodynamic characteristics of travelling at 1,000mph. Simulations have looked at how the car will cope with the supersonic rolling ground, rotating wheels and resulting shock waves in close proximity to the test surface at the record attempt site in Hakskeen Pan, South Africa. Where, in 2015, it will make high speed test runs of up to 800mph, with the full 1,000mph attempt scheduled for 2016.
...
Odds that global warming is due to natural factors: Slim to none
2014-04-11
An analysis of temperature data since 1500 all but rules out the possibility that global warming in the industrial era is just a natural fluctuation in the earth's climate, according to a new study by McGill University physics professor Shaun Lovejoy.
The study, published online April 6 in the journal Climate Dynamics, represents a new approach to the question of whether global warming in the industrial era has been caused largely by man-made emissions from the burning of fossil fuels. Rather than using complex computer models to estimate the effects of greenhouse-gas ...
Warming climate has consequences for Michigan's forests
2014-04-11
HOUGHTON, Mich., April 11, 2014 – In the last 100 years, Michigan has become warmer, with more rain coming through heavy downpours. Climate models suggest that the state will continue to warm and variability in precipitation patterns will increase, which will have consequences for the state's forests. A new U.S. Forest Service report describes the potential risks and opportunities of climate change for forests in the eastern Upper Peninsula and northern Lower Peninsula.
More than 30 scientists and forest managers contributed to "Michigan Forest Ecosystem Vulnerability ...
Berkeley graduate student brings extinct plants to life
2014-04-11
Jeff Benca is an admitted über-geek when it comes to prehistoric plants, so it was no surprise that, when he submitted a paper describing a new species of long-extinct lycopod for publication, he ditched the standard line drawing and insisted on a detailed and beautifully rendered color reconstruction of the plant. This piece earned the cover of March's centennial issue of the American Journal of Botany.
"Typically, when you see pictures of early land plants, they're not that sexy: there is a green forking stick and that's about it. We don't have many thorough reconstructions," ...
Facial selection technique for ads can increase buyers by 15 percent: INFORMS Marketing Science
2014-04-11
Merely changing the face of a model in an ad increases the number of potential purchasers by as much as 15% (8% on average), according to a study being published by the Institute for Operations Research and the Management Sciences (INFORMS).
"Just the Faces: Exploring the Effects of Facial Features in Print Advertising," appears in the Articles in Advance section of the INFORMS journal Marketing Science and will appear in print later this year. The research was conducted by Li Xiao, Assistant Professor of Marketing at Fudan University (China), and Min Ding, Smeal Professor ...
Sudden loss of consciousness
2014-04-11
According to a prospective study (the SPEED Study) presented by Yvonne Greve of Nuremberg Hospital et al. in Deutsches Ärzteblatt International (Dtsch Arztebl Int 2014; 111(12): 197), up to 3% of consultations at an emergency department concern a sudden loss of consciousness or near loss of consciousness.
In order to assess the frequency and prognostic significance of near syncope and syncope (the specialist terms for short-term near or complete loss of consciousness), the authors gathered data on 395 patients who presented to an emergency department with the typical ...